Latest News

Updated interim data from a phase 1/2 study of the DR5 agonist ozekibart plus FOLFIRI demonstrated a 20% ORR and 87% DCR in late-line colorectal cancer.

New findings from the AACR Annual Meeting revealed risk factors for locoregional recurrence in patients diagnosed with breast cancer at age 40 or younger.

Early trials exploring the efficacy of PD-1 blockade in Hodgkin lymphoma inspired the SWOG S1826 trial, which evaluated the agent with AVD in this population.

Surgical approach and adherence to endocrine therapy were predictors of locoregional recurrence in women diagnosed with breast cancer at age 40 or younger.

All patients who received cilta-cel in the phase 2 CAR-PRISM trial achieved MRD negativity per next-generation sequencing.

Data from the phase 2 MATISSE trial could pave the way for CD39 and adenosine pathway inhibition in early-stage non–small cell lung cancer.

Key data from the ATLAS-IT-05 study showed the activity of the oncolytic peptide ruxotemitide plus pembrolizumab in refractory metastatic melanoma.

The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.

A numerical survival improvement was observed with ramucirumab plus pembrolizumab among those with squamous cell carcinoma in a phase 2 study.

Experts discussed the evolving landscape of EGFR-mutated NSCLC, focusing on the practice-changing results of the ADAURA and NeoADAURA trials.

Minimal residual disease negativity may negate the need to wait 5 to 10 years for updated findings to inform treatment decision-making in multiple myeloma.

Explore how ADCs, ctDNA monitoring, and new endocrine options reshape metastatic breast cancer care, as well as sequencing and toxicity tips from experts.

The panel discussed key considerations in the relapsed/refractory setting, including toxicity management and sequencing strategies for targeted agents.

Diane Simeone, MD, discussed efficacy results from the phase 3 RASolute 302 trial evaluating daraxonrasib in patients with metastatic pancreatic cancer.

Paul Nathan, MBBS, PhD, FRCP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01–positive uveal melanoma.

The 5-year OS rate was 16% and 8% in the tebentafusp and control arms, respectively, for patients with HLA-A*02:01–positive uveal melanoma.

Data from the phase 3 DREAMM-7 trial support the approval of belantamab mafodotin plus bortezomib and dexamethasone for patients in China.

Findings from the phase 3 EV-304 trial support the supplemental biologics license application for enfortumab vedotin/pembrolizumab in patients with MIBC.

Presenters at the 3rd Biennial Miami Precision Medicine 2026 Conference shared insights related to pancreatic cancer, sarcomas, and genitourinary diseases.

Data from the Beamion LUNG-1 trial may help clinicians make informed decisions on HER2-targeted therapy for those with advanced or metastatic NSCLC.

Iberdomide and mezigdomide have achieved positive phase 3 results in multiple myeloma, according to Shebli Atrash, MD.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI algorithm can complement tools such as the Tyrer-Cuzick model to define breast cancer risks.

Orca-T has demonstrated clear benefits in reducing graft-vs-host disease among patients with hematologic malignancies, according to Wendy Stock, MD.

All injections of JNJ-1900 have been completed according to plan so far in the phase 2 CONVERGE study, said Benjamin Cooper, MD.

Constant adjustments during high-intensity focused ultrasound may help minimize damage to healthy tissue in prostate cancer treatment.

Experts discuss the “transformational” potential of enfortumab vedotin plus pembrolizumab for patients with muscle-invasive bladder cancer.

Sarah Weiss, MD, discussed key IGNYTE trial findings of RP1 and nivolumab in patients with advanced melanoma who progressed on prior anti-PD-1 therapy.

Heath Skinner, MD, PhD, discussed current standards for radiotherapy in head and neck cancers and highlighted multidisciplinary collaboration within UPMC.

Zenocutuzumab has been added to the NCCN’s Clinical Practice Guidelines in Oncology for biliary tract cancers based on results from the phase 2 eNRGy trial.

Among patients with recurrent cervical cancer who received prior immunotherapy, sac-TMT plus pembrolizumab achieved an ORR of 54%.